The Role of Clopidogrel and Acetylsalicylic Acid in the Prevention of Early-Phase Graft Occlusion Due to Reactive Thrombocytosis after Coronary Artery Bypass Operation
DOI:
https://doi.org/10.1532/HSF98.20071196Abstract
Background. Reactive thrombocytosis has been reported in 20% of patients after coronary artery bypass grafting (CABG), a frequency that might be related to the high incidence of thrombotic complications. The present study was planned to investigate the effect of combined treatment with clopidogrel and acetylsalicylic acid (ASA) on post-CABG reactive thrombocytosis.
Methods. Included in this prospective, randomized study were 60 patients who underwent CABG operation with a 6-month follow-up. Three study groups were defined: group 1 (n = 20), a control group of patients who have not developed reactive thrombocytosis after CABG surgery; group 2 (n = 20), patients who have developed reactive thrombocytosis and continue taking ASA (300 mg/day); and group 3 (n = 20), patients who have developed reactive thrombocytosis and continue taking ASA (300 mg/day) with the addition of clopidogrel (75 mg/day).
Results. The mean ages and sex distributions of the patient groups were similar. There were no significant differences between the groups regarding cardiovascular risk factors, baseline laboratory findings, or intraoperative characteristics. Thrombocytosis disappeared within the first month after the operation in both treatment groups. An evaluation of graft patency in the sixth postoperative month revealed that group 2 had significantly more patients with a "positive" result in the exercise test than group 3 and that group 3 had a lower incidence of graft occlusion than group 2 (P < .01).
Conclusions. Combination antiplatelet therapy with ASA and clopidogrel seems to be more effective than ASA alone for maintaining graft patency in patients with reactive thrombocytosis.
References
Blatt DL, Chew DP, Hirsh AT, Ringleb PA, Hacke W, Topol EJ. 2001. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103:363-8.nBruce RA, Kussumi F, Hosmere D. 1973. Maximal oxygen intake and normographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 85:546-62.nCAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-39.nChesebro JH, Clements IP, Fuster V, et al. 1982. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 307:73-8.nChristenson JT, Gras PA, Grosclaude A, Simonet F, Schmuziger M. 1996. Reactive thrombocytosis following coronary artery bypass surgery: a possible link to a lipid dysfunction. J Cardiovasc Surg (Torino) 37:491-8.nCURE Trial Investigators. 2001. Effects of clopidogrel addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502.nFitzGibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. 1996. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28:616-26.nFitzGibbon GM, Leach AJ, Keon WJ, Burton JR, Kafka HP. 1986. Coronary bypass graft fate: angiographic study of 1,179 vein grafts early, one year, and five years after operation. J Thorac Cardiovasc Surg 91:773-8.nGoldman S, Copeland J, Moritz MI, et al. 1988. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77:1324-32.nJohnson WD, Brenowitz JB, Kayser KL. 1989. Factors influencing long-term (10-year to 15-year) survival after a successful coronary artery bypass operation. Ann Thorac Surg 48:19-25.nLichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafflenbeul W. 1992. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated quantitated coronary angiography: relation to clinical events and risk factors. The INTACT Study Group. Circulation 86:828-38.nLorenz RL, Scharky CV, Weber M, et al. 1984. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation. Lancet 1:1261-4.nMcKenzie FN, Dhall DP, Arfors KE, Nordlung S, Matheson NA. 1969. Blood platelet behaviour during and after open-heart surgery. Br Med J 2:795-8.nMessinezy M, Westwood N, Sawyer B, et al. 1994. Primary thrombocythaemia: a composite approach to diagnosis. Clin Lab Haematol 16:139-48.nMotwani JG, Topol EJ. 1998. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97:916-31.nPackham MA, Mustard JF. 1986. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 23:8-26.nQuinn MJ, Fitzgerald DJ. 1999. Ticlopidine and clopidogrel. Circulation 100:1667-72.nRoberts AJ, Spies SM, Sanders JH, et al. 1981. Serial assessment of left ventricular performance following coronary artery bypass grafting: early postoperative results with myocardial protection afforded by multidose hypothermic potassium crystalloid cardioplegia. J Thorac Cardiovasc Surg 81:69-84.nSchmuziger M, Christenson JT, Maurice J, Simonet F, Velebit V. 1995. Reactive thrombocytosis after coronary bypass surgery: an important risk factor. Eur J Cardiothorac Surg 9:393-8.nAinsworth BE, Haskell WL, Whitt MC, et al. 2000. Compendium of physical activities and update of activity codes and MET intensities. Med Sci Sports Exerc 32:S498-504.n
